 |
|
|
 |
Increased Awareness of Stroke Symptoms Could Dramatically Reduce Stroke Disability
Only a fraction of stroke patients each year are getting to the hospital in time to receive a treatment that makes the difference between disability and full recovery. Thousands more people could benefit from the treatment -- a drug called tissue plasminogen activator (t-PA)-- but do not, often because they do not know the symptoms of stroke or do not get to the hospital within the drug's 3-hour window of effectiveness. The National Institute of Neurological Disorders and Stroke (NINDS) is launching a national public education campaign, Know Stroke: Know the Signs. Act in Time, to help people overcome these barriers and to get medical help in time. more
|
|
Information For Patients: Brain Basics - Preventing Stroke
Stroke ranks as the third leading killer in the United States. A stroke can be devastating to individuals and their families, robbing them of their independence. It is the most common cause of adult disability. Each year more than 500,000 Americans have a stroke, with about 145,000 dying from stroke-related causes. Officials at the National Institute of Neurological Disorders and Stroke (NINDS) are committed to reducing that burden through biomedical research. Get this fact sheet for patients, courtesy of the NINDS. more
|
|
|
|
NCI-Sponsored Trial Tests Shark Cartilage Extract
The National Cancer Institute (NCI) has launched a large, randomized clinical trial to test the effects of shark cartilage in combination with chemotherapy and radiotherapy in patients with non-small cell lung cancer (NSCLC) that cannot be removed by surgery. The study will take place at more than 50 sites throughout the United States and Canada and seeks to enroll 756 patients over the next three years. more
|
|
Trials Will Test STI-571 (Glivec) In More Cancers
The drug STI-571 is now in clinical trials for glioblastoma, for gastrointestinal stromal tumors and leukemia under a new agreement between the National Cancer Institute and Novartis Pharmaceuticals, the company that makes STI-571. Initially tested in chronic myelogenous leukemia, the experimental drug has also shown promise for some solid tumors. more
|
|
Update: Background On STI-571 (Glivec)
STI-571 is a part of a growing group of molecularly targeted treatments in which drugs are designed to treat diseases with specific genetic changes. Research studies in 2000 revealed that STI-571 may also be effective in treating certain types of brain and stomach cancers and clinical trials are underway to further determine its usefulness. more
|
|
|
